Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety, Tolerability and Efficacy of OMS906 in PNH
2023-507413-10-00Phase 2Authorised
- Sponsor
- Omeros Corporation
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Omeros Corporation. Planned start May 2024; status: authorised.
02
Drugs
zaltenibart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2023-507413-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507413-10-00.